Alcohol Use DisorderNCT02994043
Alcohol, Inflammation, and Mindfulness Study (AIM)
A study testing Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy in people with Alcohol Use Disorder, run by University of Colorado, Denver at 1 site in United States.
Trial summary
The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Alcohol Use Disorder
- What is being tested?
- Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 182 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2016to 17 Feb 2021
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder;
- Must be within 10 days of last drink;
- Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time;
- Must have a breath alcohol level of 0 at screening;
- Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox);
- Must have expressed a desire during their initial screen to reduce the number of drinks they regularly consume
Who cannot join
- Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis;
- Pregnant, as indicated by a pregnancy test which will be administered at baseline;
- Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;
- Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Colorado Denver
Denver, Colorado, 80045
About this study
Official title: Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.
The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.
Read the detailed description
This study was designed to evaluate the effect of two outpatient, individually-administered, psychosocial interventions (Relapse Prevention vs. Mindfulness-Based Relapse Prevention). Participants are recruited via mass media advertisements, flyers, and local outreach to clinical providers that do not address substance use. We will recruit 226 individuals. Our previous experience with clinical trials, as well as the experience of our research team members with these interventions support the feasibility of recruiting approximately 50 patients per year. This sample size provides adequate statistical power for the research questions undertaken.
Participants are screened over the telephone and invited into the laboratory for a baseline assessment. Immediately after the baseline assessment, they are randomized to a therapist and then to a treatment condition. At the end of each year, the distribution of participants across conditions and therapists are evaluated for imbalances. If attrition has resulted in an imbalance across conditions, the randomization procedure will be adjusted to ensure equal numbers of participants in RP and MBRP.
Within a week of completing the baseline assessments, participants are seen by their individual therapist for a motivational interviewing, goal-setting session. After the goal-setting session, the eight-session MBRP or RP treatments are administered. To ensure that therapists adhere to treatment manuals, a checklist is provided consisting of the primary content addressed each session (four to seven primary content pieces each session). Further, questionnaires assessing mindfulness practice and facets of mindfulness (e.g., being nonjudgmental, nonreactive) are administered at each assessment. At the most recent RPPR, these questionnaires validated that participants in the MBRP condition were increasing in some facets of mindfulness during treatment (and up to three months after treatment).
We estimate that the completion of assessments and procedures across the duration of the trial, excluding therapy sessions, will total about 15 hours of time. To compensate subjects for their time and travel costs, each subject will be paid $300 if they complete all sessions.
We will conduct extensive analyses of any attrition encountered in the project to determine bias. However, note that in each of the analyses described herein, we will have the capability of using modern approaches to the handling of missing data including full information maximum likelihood estimation of missing data within Proc Mixed in SAS and within EQS.
The distributional properties of all continuously scaled variables will be examined for skewness and kurtosis to determine the need for normalizing transformations or for alternations to our analysis plan (i.e., generalized estimating equations or robust estimation) prior to the primary analyses.
To confirm the validity of random assignment, pretest equivalence of the two treatment conditions across demographics, drinking history, smoking, and all other baseline measures will be assessed via t-tests on continuous items and c2 tests of categorical items. We will use the Bonferroni approach to correct for alpha inflation with a familywise alpha of .05. Any variables on which the two groups are unequal at pretest will be covariates in all further analyses.
Attrition analyses will be conducted after each follow-up data collection effort to provide assurance that differential attrition by treatment condition has not occurred. Following previously published procedures, a series of ANOVAs of treatment (MBRP versus RP) X retention (retained, not retained) will be conducted on continuous baseline measures. Significant treatment X retention interactions identify measured variables on which differential attrition may have occurred. The logit model analog procedure will be applied to categorical baseline measures to test for differential attrition on categorical variables such as gender and ethnicity. We will conduct these analyses to assure that differential attrition by treatment condition does not account for any of the effects of the treatments.
- Conditions
- Alcohol Use Disorder
- Being tested
- Mindfulness-Based Relapse Prevention Therapy, Relapse Prevention Therapy
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mindfulness-Based Relapse Prevention TherapyBehavioural
An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
Relapse Prevention TherapyBehavioural
An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
| Study group | Role | What they receive |
|---|---|---|
| MBRP | Active comparator | Not described Receives: Behavioral: Mindfulness-Based Relapse Prevention Therapy |
| RP | Active comparator | Not described Receives: Behavioral: Relapse Prevention Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heavy Drinking Days at Baseline
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Measured: Baseline
Heavy Drinking Days at Week 4
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Measured: Week 4
Heavy Drinking Days at Week 8
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Measured: Week 8
Heavy Drinking Days at Week 20
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Measured: Week 20
Heavy Drinking Days at Week 32
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Measured: Week 32
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2016 (estimated)
- Study start9 Nov 2016
- Primary completion17 Feb 2021
- Study completion17 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 182 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Collaborators
- University of Colorado, Boulder, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Responsible party
- Sponsor
- Investigators
- Ken Hutchison, Principal investigator, University of Colorado Denver | Anschutz
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02994043
- Sponsor's protocol ID
- 20-2550
- Other IDs
- R01AA024632
- Status last verified
- Dec 2022
- First submitted
- 12 Dec 2016
- Last updated
- 19 Jan 2023
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Skrzynski CJ, Karoly H, Ellingson JM, Hagerty SL, Bryan AD, Hutchison KE. Comparing the Efficacy of Mindfulness-Based Relapse Prevention Versus Relapse Prevention for Alcohol Use Disorder: A Randomized Control Trial. J Stud Alcohol Drugs. 2023 Jul;84(4):560-569. doi: 10.15288/jsad.21-00392. Epub 2023 Feb 1.
PubMed 36971735Karoly HC, Skrzynski CJ, Moe EN, Bryan AD, Hutchison KE. Exploring relationships between alcohol consumption, inflammation, and brain structure in a heavy drinking sample. Alcohol Clin Exp Res. 2021 Nov;45(11):2256-2270. doi: 10.1111/acer.14712. Epub 2021 Sep 22.
PubMed 34523725Karoly HC, Ross JM, Prince MA, Zabelski AE, Hutchison KE. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021 Sep;116(9):2529-2537. doi: 10.1111/add.15407. Epub 2021 Jan 26.
PubMed 33464670
Study at a glance
From the registry record, last updated by the sponsor on 19 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.
- ClinicalTrials.gov ID
- NCT02994043
- Acronym / sponsor ID
- 20-2550
- Conditions
- Alcohol Use Disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 182 participants (actual)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- University of Colorado, Boulder, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Study start
- 9 Nov 2016 (actual)
- Primary completion
- 17 Feb 2021 (actual)
- Study completion
- 17 Feb 2021 (actual)
- First posted
- 15 Dec 2016 (estimated)
- Results
- Posted 19 Jan 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.
Detailed description
This study was designed to evaluate the effect of two outpatient, individually-administered, psychosocial interventions (Relapse Prevention vs. Mindfulness-Based Relapse Prevention). Participants are recruited via mass media advertisements, flyers, and local outreach to clinical providers that do not address substance use. We will recruit 226 individuals. Our previous experience with clinical trials, as well as the experience of our research team members with these interventions support the feasibility of recruiting approximately 50 patients per year. This sample size provides adequate statistical power for the research questions undertaken.
Participants are screened over the telephone and invited into the laboratory for a baseline assessment. Immediately after the baseline assessment, they are randomized to a therapist and then to a treatment condition. At the end of each year, the distribution of participants across conditions and therapists are evaluated for imbalances. If attrition has resulted in an imbalance across conditions, the randomization procedure will be adjusted to ensure equal numbers of participants in RP and MBRP.
Within a week of completing the baseline assessments, participants are seen by their individual therapist for a motivational interviewing, goal-setting session. After the goal-setting session, the eight-session MBRP or RP treatments are administered. To ensure that therapists adhere to treatment manuals, a checklist is provided consisting of the primary content addressed each session (four to seven primary content pieces each session). Further, questionnaires assessing mindfulness practice and facets of mindfulness (e.g., being nonjudgmental, nonreactive) are administered at each assessment. At the most recent RPPR, these questionnaires validated that participants in the MBRP condition were increasing in some facets of mindfulness during treatment (and up to three months after treatment).
We estimate that the completion of assessments and procedures across the duration of the trial, excluding therapy sessions, will total about 15 hours of time. To compensate subjects for their time and travel costs, each subject will be paid $300 if they complete all sessions.
We will conduct extensive analyses of any attrition encountered in the project to determine bias. However, note that in each of the analyses described herein, we will have the capability of using modern approaches to the handling of missing data including full information maximum likelihood estimation of missing data within Proc Mixed in SAS and within EQS.
The distributional properties of all continuously scaled variables will be examined for skewness and kurtosis to determine the need for normalizing transformations or for alternations to our analysis plan (i.e., generalized estimating equations or robust estimation) prior to the primary analyses.
To confirm the validity of random assignment, pretest equivalence of the two treatment conditions across demographics, drinking history, smoking, and all other baseline measures will be assessed via t-tests on continuous items and c2 tests of categorical items. We will use the Bonferroni approach to correct for alpha inflation with a familywise alpha of .05. Any variables on which the two groups are unequal at pretest will be covariates in all further analyses.
Attrition analyses will be conducted after each follow-up data collection effort to provide assurance that differential attrition by treatment condition has not occurred. Following previously published procedures, a series of ANOVAs of treatment (MBRP versus RP) X retention (retained, not retained) will be conducted on continuous baseline measures. Significant treatment X retention interactions identify measured variables on which differential attrition may have occurred. The logit model analog procedure will be applied to categorical baseline measures to test for differential attrition on categorical variables such as gender and ethnicity. We will conduct these analyses to assure that differential attrition by treatment condition does not account for any of the effects of the treatments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MBRP | Active comparator | Behavioral: Mindfulness-Based Relapse Prevention Therapy |
| RP | Active comparator | Behavioral: Relapse Prevention Therapy |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder;
- Must be within 10 days of last drink;
- Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time;
- Must have a breath alcohol level of 0 at screening;
- Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox);
Key exclusion criteria (4 listed)
- Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis;
- Pregnant, as indicated by a pregnancy test which will be administered at baseline;
- Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;
- Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mindfulness-Based Relapse Prevention TherapyAn 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention. | Behavioural | MBRP |
| Relapse Prevention TherapyAn 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences. | Behavioural | RP |
Primary outcome
Heavy Drinking Days at Baseline
Time frame: Baseline
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 4
Time frame: Week 4
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 8
Time frame: Week 8
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 20
Time frame: Week 20
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 32
Time frame: Week 32
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jan 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36971735Skrzynski CJ, Karoly H, Ellingson JM, Hagerty SL, Bryan AD, Hutchison KE. Comparing the Efficacy of Mindfulness-Based Relapse Prevention Versus Relapse Prevention for Alcohol Use Disorder: A Randomized Control Trial. J Stud Alcohol Drugs. 2023 Jul;84(4):560-569. doi: 10.15288/jsad.21-00392. Epub 2023 Feb 1.
- Derived from this study: PubMed 34523725Karoly HC, Skrzynski CJ, Moe EN, Bryan AD, Hutchison KE. Exploring relationships between alcohol consumption, inflammation, and brain structure in a heavy drinking sample. Alcohol Clin Exp Res. 2021 Nov;45(11):2256-2270. doi: 10.1111/acer.14712. Epub 2021 Sep 22.
- Derived from this study: PubMed 33464670Karoly HC, Ross JM, Prince MA, Zabelski AE, Hutchison KE. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021 Sep;116(9):2529-2537. doi: 10.1111/add.15407. Epub 2021 Jan 26.
- Individual participant dataSharing planned: No
Related trials for Alcohol Use Disorder
Recruiting
Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
Alcohol Use Disorder, Addiction
Not yet recruitingPhase 1/2
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Alcohol Withdrawal, Alcohol Abstinence
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
RecruitingPhase 2
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Alcohol Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ken Hutchison principal investigator
University of Colorado Denver | Anschutz
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy in people with Alcohol Use Disorder, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Jan 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heavy Drinking Days at Baseline (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02994043, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2023.